Navigation Links
Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
Date:9/25/2008

EATONTOWN, N.J., Sept. 25 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today the appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors. Dr. Laurencin joined the Board of Directors effective September 24, 2008 and will serve on both the Audit and the Compensation Committees of the Board of Directors.

Kenneth P. Fallon, III, Chairman of the Board of Directors, commented, "We are excited about the addition of Dr. Laurencin to Osteotech's Board. Cato's experience and expertise as a nationally prominent orthopaedic surgeon will be of great assistance in helping the Board support the Company's new product development initiatives furthering its long-term growth objectives."

Since August 2008, Dr. Laurencin has been the Vice President for Health Affairs and the Dean of the School of Medicine at the University of Connecticut. Dr. Laurencin holds the Albert and Wilda Van Dusen Endowed Chair in Academic Medicine and is the Distinguished Professor of Orthopaedic Surgery at the University of Connecticut. Previously, Dr. Laurencin was the Lillian T. Pratt Distinguished Professor and the Chair of the Department of Orthopaedic Surgery at the University of Virginia and the Orthopaedic Surgeon-in-Chief at the University of Virginia Health System. Dr. Laurencin has been widely published in scholarly journals and holds more than twenty U.S. patents. He is also a member of the Institute of Medicine of the National Academy of Sciences.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com .


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
2. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
5. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
6. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
7. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
8. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
9. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
10. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
11. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Baltimore, Maryland (PRWEB) , ... ... ... firm, PathSensors, Inc., announced today that in a published evaluation of multiple ... (PNNL), a U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection ...
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 non-profit, ... is to advance global health and highlight the greater good of clinical trial participation ... trial volunteer. The vision of GGI is to serve as a philanthropic connector between ...
(Date:2/23/2017)... and SAN FRANCISCO , ... privately-held regenerative medicine company, and Beyond Type 1, a ... type 1 diabetes, today announced a grant from Beyond ... functional cure for type 1 and other insulin-requiring diabetes.  ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a neurotechnology ... for research and clinical applications. The terms of the transaction were not disclosed. ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):